A novel cooled laser focal therapy device demonstrates 84% treatment success for localized prostate cancer at 3 months, with only 12% reporting erectile dysfunction and minimal impact on urinary ...

Because treatment of the whole prostate can lead to long-term side effects in patients with prostate cancer, interest in minimally invasive, focal treatment options has been growing for certain ...

Lu-177 vipivotide tetraxetan shifted from post-taxane mCRPC to pre-chemotherapy mCRPC and then metastatic hormone-sensitive ...

Answer: About 1 in 8 men will be diagnosed with prostate cancer during their lifetime, making it one of the most diagnosed ...

Because treatment of the whole prostate can lead to long-term side effects in patients with prostate cancer, interest in minimally invasive, focal treatment options has been growing for certain ...

Men will be able to receive laser treatment for benign enlarged prostates at King Edward VII Memorial Hospital in the new year. The Argus Group donated $52,500 for the purchase of a GreenLight XPS ...

While NEPC rarely arises de novo and represents <1% of new prostate cancer diagnoses, up to 15%-20% of late-stage prostate cancers can develop AR-independent NEPC features. 68 In its pure form, NEPC ...

A new at-home saliva test could help identify men with a high risk of prostate cancer more accurately than blood tests, leading to earlier diagnosis and more successful treatment. Prostate cancer is ...